Status:
COMPLETED
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
Lead Sponsor:
Novartis
Conditions:
Genital Herpes
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a re...
Eligibility Criteria
Inclusion
- Males or non-pregnant females at least 18 years of age with HSV-2 seropositive serology with or without history of clinically diagnosed recurrent genital herpes
Exclusion
- Pregnancy
- History of renal dysfunction
- Use of immunosuppressive therapy, including steroids (other than topical or inhaled), or use of probenecid
- Hypersensitivity to famciclovir, valacyclovir or drugs with similar chemical structure
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00129818
Start Date
July 1 2004
End Date
October 1 2005
Last Update
April 27 2012
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
3
IU Center for Clinical STD Research
Indianapolis, Indiana, United States, 46202
4
UNC Clinical Research - Raleigh
Raleigh, North Carolina, United States, 27607